Generalized pustular psoriasis successfully treated with spesolimab: A case report
- PMID: 38419797
- PMCID: PMC10901063
- DOI: 10.1177/2050313X241235451
Generalized pustular psoriasis successfully treated with spesolimab: A case report
Abstract
Generalized pustular psoriasis is defined as a primary, sterile, macroscopically visible pustular eruption on non-acral skin, which can occur with or without systemic inflammation and/or psoriasis vulgaris, and can either be relapsing or be persistent, according to the European Rare and Severe Psoriasis Expert Network. The treatment of generalized pustular psoriasis may be challenging. We describe a 48-year-old woman with a 15-year history of severe generalized pustular psoriasis and plaque psoriasis resistant to multiple courses of treatments with conventional and biological agents who had a rapid, complete and durable (up to 12 months) clinical remission with spesolimab, an anti-interleukin-36 receptor antagonist monoclonal antibody recently approved for the treatment of generalized pustular psoriasis flares.
Keywords: Generalized Pustular Psoriasis Physician Global Assessment; Generalized pustular psoriasis; IL-36; spesolimab.
© The Author(s) 2024.
Conflict of interest statement
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Paolo Gisondi has been consultant in advisory board and/or served as a speaker for AbbVie, Biogen, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi, and UCB Pharma; Giampiero Girolomoni has received personal fees from AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Leo Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung bioepis and Sanofi; Francesco Bellinato and Noemi Brigenti none declared.
Figures


Similar articles
-
Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval.Front Immunol. 2024 Jul 22;15:1359481. doi: 10.3389/fimmu.2024.1359481. eCollection 2024. Front Immunol. 2024. PMID: 39104539 Free PMC article. Review.
-
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.Dermatol Ther (Heidelb). 2023 Jan;13(1):347-359. doi: 10.1007/s13555-022-00835-6. Epub 2022 Nov 5. Dermatol Ther (Heidelb). 2023. PMID: 36333618 Free PMC article.
-
Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.J Dermatol. 2023 Feb;50(2):183-194. doi: 10.1111/1346-8138.16609. Epub 2022 Oct 25. J Dermatol. 2023. PMID: 36282833 Free PMC article. Clinical Trial.
-
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.J Am Acad Dermatol. 2023 Jul;89(1):36-44. doi: 10.1016/j.jaad.2023.02.040. Epub 2023 Mar 2. J Am Acad Dermatol. 2023. PMID: 36870370 Clinical Trial.
-
Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date.Psoriasis (Auckl). 2024 Mar 15;14:23-27. doi: 10.2147/PTT.S393978. eCollection 2024. Psoriasis (Auckl). 2024. PMID: 38505140 Free PMC article. Review.
Cited by
-
Successful Treatment of Pediatric Generalized Pustular Psoriasis (GPP) with Spesolimab: 5 Case Reports and Evaluations of Circulating IL-36 Levels.J Inflamm Res. 2024 Nov 4;17:8199-8206. doi: 10.2147/JIR.S485077. eCollection 2024. J Inflamm Res. 2024. PMID: 39525315 Free PMC article.
-
Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval.Front Immunol. 2024 Jul 22;15:1359481. doi: 10.3389/fimmu.2024.1359481. eCollection 2024. Front Immunol. 2024. PMID: 39104539 Free PMC article. Review.
References
-
- Navarini AA, Burden AD, Capon F, et al.. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 1792–1799. - PubMed
-
- Löfvendahl S, Norlin JM, Schmitt-Egenolf M. Prevalence and incidence of generalized pustular psoriasis in Sweden: a population-based register study. Br J Dermatol 2022; 186(6): 970–976. - PubMed
-
- Bachelez H, Choon SE, Marrakchi S, et al.. Inhibition of the Interleukin-36 Pathway for the treatment of generalized pustular psoriasis. N Engl J Med 2019; 380(10): 981–983. - PubMed
Publication types
LinkOut - more resources
Full Text Sources